Blog
RSS FeedPosted by Michael Wonder on 06 Mar 2022
Australian COVID nasal spray not on shop shelves amid TGA dispute
4 March 2022 - Melbourne start-up Starpharma is at loggerheads with the medicines regulator over the approvals process for its ...
Posted by Michael Wonder on 03 Mar 2022
Medicines Australia welcomes reform efforts to speed up clinical trials
4 March 2022 - Australian patients will have improved access to clinical trials due to reforms to be introduced by ...
Posted by Michael Wonder on 03 Mar 2022
COVID-19 vaccine weekly safety report (3 March 2022)
3 March 2022 - This is the 52nd issue of the COVID-19 vaccine safety report. ...
Posted by Michael Wonder on 03 Mar 2022
Jemperli approved by the TGA
2 March 2022 - Dostarlimab is an anti-programmed cell death protein 1 immunoglobulin G4 humanised monoclonal antibody, derived from a stable ...
Posted by Michael Wonder on 02 Mar 2022
ATAGI recommends Novavax for use as a COVID-19 booster
2 March 2022 - The Australian Technical Advisory Group on Immunisation has recommended the use of the Novavax vaccine as a ...
Posted by Michael Wonder on 28 Feb 2022
ATAGI update following weekly COVID-19 meeting (23 February 2022)
28 February 2022 - ATAGI recommends Spikevax (Moderna) COVID-19 vaccine can be used for primary vaccination in children aged 6-11 ...
Posted by Michael Wonder on 28 Feb 2022
Prescription medicines: applications under evaluation (February 2022)
25 February 2022 - The TGA has updated its list of applications for new medicines or new uses for existing ...
Posted by Michael Wonder on 25 Feb 2022
TGA provisionally approves AstraZeneca's combination therapy (tixagevimab and cilgavimab, Evusheld) - for pre-exposure prevention (prophylaxis) of COVID-19
25 February 2022 - On 24 February 2022, the TGA granted provisional approval to AstraZeneca for its tixagevimab and cilgavimab ...
Posted by Michael Wonder on 24 Feb 2022
COVID-19 vaccine weekly safety report (24 February 2022)
24 February 2022 - To 20 February 2022, the TGA has received 451 reports which have been assessed as likely to ...
Posted by Michael Wonder on 24 Feb 2022
ATAGI recommendations on the use of Spikevax (Moderna) COVID-19 vaccine in children aged 6 to 11 years
23 February 2022 - The Australian Technical Advisory Group on Immunisation (ATAGI) has made recommendations for the use of the Moderna ...
Posted by Michael Wonder on 23 Feb 2022
TGA checks need for another vax booster
23 February 2022 - Australia is looking at whether to offer a fourth COVID dose ahead of the flu season ...
Posted by Michael Wonder on 23 Feb 2022
‘Grumpy’ TGA boss unloads over people downplaying COVID’s effect on kids
23 February 2022 - The head of Australia’s medicines regulator has unloaded on those downplaying the effect COVID-19 has on ...
Posted by Michael Wonder on 22 Feb 2022
Controversial Alzheimer’s drug under TGA review ‘should not be approved’
21 February 2022 - Patients will be put at risk and taxpayers will face a significant economic burden if aducanumab receives ...
Posted by Michael Wonder on 22 Feb 2022
TGA approves Rybelsus
22 February 2022 - Rybelsus is a new formulation of semaglutide. ...
Posted by Michael Wonder on 17 Feb 2022
COVID-19 vaccine weekly safety report (17 February 2022)
17 February 2022 - To 13 February 2022, the TGA has received 449 reports which have been assessed as likely to ...